TIG Advisors LLC Decreases Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

TIG Advisors LLC reduced its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 57.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,709 shares of the company’s stock after selling 97,335 shares during the quarter. TIG Advisors LLC’s holdings in Maravai LifeSciences were worth $385,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of MRVI. Performa Ltd US LLC lifted its stake in Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after acquiring an additional 4,300 shares during the period. FNY Investment Advisers LLC raised its holdings in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after purchasing an additional 6,000 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after purchasing an additional 9,916 shares during the period. Cibc World Markets Corp purchased a new stake in Maravai LifeSciences in the fourth quarter worth approximately $56,000. Finally, Atria Investments Inc bought a new stake in Maravai LifeSciences in the 4th quarter worth approximately $58,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Trading Down 2.0 %

Maravai LifeSciences stock opened at $2.01 on Tuesday. The stock has a market cap of $511.22 million, a P/E ratio of -1.23 and a beta of 0.18. Maravai LifeSciences Holdings, Inc. has a 1 year low of $1.67 and a 1 year high of $11.56. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. The firm’s 50 day moving average price is $2.41 and its 200-day moving average price is $4.56.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on MRVI. Robert W. Baird downgraded Maravai LifeSciences from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $9.00 to $3.00 in a research note on Wednesday, February 26th. UBS Group dropped their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a report on Friday, March 21st. Bank of America reduced their target price on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Morgan Stanley reduced their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Tuesday, March 25th. Finally, Stifel Nicolaus set a $5.00 price target on Maravai LifeSciences in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.34.

Insider Transactions at Maravai LifeSciences

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the sale, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.63% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.